CEACAM5 and neoplasm: When used to discriminate patients with LAD from healthy controls, serum levels of two ecDNAs achieved higher areas under the curve (AUCs) than serum carcinoembryonic antigen (CEA) and CYFRA21-1 (cytokeratin 19 fragments), which are among the most sensitive LAD tumor biomarkers (73).